Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Francesca Bruce
In withdrawing its European marketing application for Translarna in cystic fibrosis, PTC Therapeutics has bid farewell to a market opportunity once pegged at $700m.
The pan-Canadian Pharmaceutical Alliance has negotiated product listing agreements with three hepatitis C drug makers in one of its first major negotiations with multiple manufacturers. The pCPA may want to negotiate more deals with several companies at once, particularly those with drugs in crowded markets.
New updates to Germany’s 2011 AMNOG healthcare reform act could lead to more conservative prescribing and benefit assessments for older products. Pricing measures were dropped but will likely resurface after September’s general elections.
Companies could lose hundreds of millions of dollars thanks to the impact of Brexit on international reference pricing. Brexit has other market access implications too, for example on the ebb and flow of parallel trade.
Plans to make pharmaceutical prices in Germany confidential are likely to be shelved, but other measures could help companies better navigate price transparency.
Companies might have to rethink their German market access strategies if new legislation is passed to informs doctors of the outcome of AMNOG benefit assessments.